Article
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
JCO precision oncology - 1 Sept 2023
Rohatgi Nitin, Rothe Michael, Mangat Pam K, Garrett-Mayer Elizabeth, Meric-Bernstam Funda, Pisick Evan, Alese Olatunji B, Reynolds Christopher M, Thota Ramya, Vaccaro Gina M, von Mehren Margaret, Arend Rebecca C, Chiu Vi K, Duvivier Herbert L, Gold Philip J, Hack Keely, Marr Alissa S, Winer Arthur, Grantham Gina N, Hinshaw Dominique C, Gregory Abigail, Halabi Susan, Schilsky Richard L
Abstract excerpt
PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket study evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancers with genomic alterations known to be drug targets. Results of a cohort of patients with solid tumors with ATM mutations treated with nivolumab plus ipilimumab are reported. METHODS: Eligible patients had...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.